Immuron Limited (IMRN)Healthcare | Biotechnology | Carlton, Australia | NasdaqCM
0.93 USD
-0.03
(-2.756%) ⇩
(April 21, 2026, 10:33 a.m.
EDT)
Short-term: ★☆☆☆☆ | Long-term: ☆☆☆☆☆ | Dividends: ☆☆☆☆☆ |
Hot Take | April 19, 2026, 1:45 a.m. EDT
Avoid; despite recent price stabilization and positive revenue headlines, the AI model predicts a severe -25.6% price drop over the next 45 days due to deteriorating technicals and a lack of earnings catalysts, while the company remains unprofitable with no dividend. |
| Model | MAE |
|---|---|
| AutoARIMA ✓ | 0.203686 |
| AutoETS | 0.203694 |
| AutoTheta | 0.217938 |
| MSTL | 0.254245 |
Forecast horizon: 45 days | Selected: AutoARIMA
| Forecast Reliability | |
|---|---|
| Score | 65% |
| H-stat | 1.60 |
| Ljung-Box p | 0.000 |
| Jarque-Bera p | 0.080 |
| Excess Kurtosis | -0.05 |
| Attribute | Value |
|---|---|
| Sector | Healthcare |
| Debt to Equity Ratio | 1.559 |
| Revenue per Share | 1.16 |
| Market Cap | 9,518,392 |
| Forward P/E | -93.15 |
| Beta | 0.36 |
| Profit Margins | -62.14% |
| Website | https://www.immuron.com.au |
| Attribute | Value |
|---|---|
| 52 Week Change | -0.44624275 |
| Address1 | 62 Lygon Street |
| Address2 | Level 3 Carlton South |
| All Time High | 28.99 |
| All Time Low | 0.677 |
| Ask | 1.04 |
| Ask Size | 1 |
| Average Daily Volume10 Day | 46,630 |
| Average Daily Volume3 Month | 26,009 |
| Average Volume | 26,009 |
| Average Volume10Days | 46,630 |
| Beta | 0.362 |
| Bid | 0.9581 |
| Bid Size | 1 |
| Book Value | 1.14096 |
| City | Carlton |
| Compensation As Of Epoch Date | 1,767,139,200 |
| Country | Australia |
| Crypto Tradeable | 0 |
| Currency | USD |
| Current Price | 0.9315 |
| Current Ratio | 8.043 |
| Custom Price Alert Confidence | HIGH |
| Date Short Interest | 1,774,915,200 |
| Day High | 0.96 |
| Day Low | 0.9 |
| Debt To Equity | 1.559 |
| Display Name | Immuron |
| Earnings Timestamp End | 1,756,728,000 |
| Earnings Timestamp Start | 1,756,378,740 |
| Ebitda | -4,739,534 |
| Ebitda Margins | -0.63388 |
| Enterprise To Ebitda | -63.954 |
| Enterprise To Revenue | 40.539 |
| Enterprise Value | 303,110,080 |
| Eps Forward | -0.01 |
| Eps Trailing Twelve Months | -0.54 |
| Esg Populated | 0 |
| Exchange | NCM |
| Exchange Data Delayed By | 0 |
| Exchange Timezone Name | America/New_York |
| Exchange Timezone Short Name | EDT |
| Fax | 61 3 9822 7735 |
| Fifty Day Average | 0.78336 |
| Fifty Day Average Change | 0.14814001 |
| Fifty Day Average Change Percent | 0.18910848 |
| Fifty Two Week Change Percent | -44.624275 |
| Fifty Two Week High | 2.39 |
| Fifty Two Week High Change | -1.4585001 |
| Fifty Two Week High Change Percent | -0.61025107 |
| Fifty Two Week Low | 0.677 |
| Fifty Two Week Low Change | 0.25450003 |
| Fifty Two Week Low Change Percent | 0.37592325 |
| Fifty Two Week Range | 0.677 - 2.39 |
| Financial Currency | AUD |
| First Trade Date Milliseconds | 1,497,015,000,000 |
| Float Shares | 322,661,902 |
| Forward Eps | -0.01 |
| Forward P E | -93.15 |
| Free Cashflow | -3,420,940 |
| Full Exchange Name | NasdaqCM |
| Full Time Employees | 7 |
| Gmt Off Set Milliseconds | -14,400,000 |
| Gross Margins | 0.63685 |
| Gross Profits | 4,761,740 |
| Has Pre Post Market Data | 1 |
| Held Percent Insiders | 0.0 |
| Held Percent Institutions | 0.02014 |
| Implied Shares Outstanding | 10,218,349 |
| Industry | Biotechnology |
| Industry Disp | Biotechnology |
| Industry Key | biotechnology |
| Is Earnings Date Estimate | 1 |
| Language | en-US |
| Last Fiscal Year End | 1,751,241,600 |
| Long Business Summary | Immuron Limited, a biopharmaceutical company, engages in the research, development, and commercialization of polyclonal antibodies in Australia, the United States, and Canada. It operates through two segments, Research and Development; and Hyper-immune Products. The company offers Travelan, an over-the-counter medicine to reduce the risk of travelers' diarrhea and risk of minor gastrointestinal disorders, as well as a dietary supplement for digestive tract protection; and Protectyn, an immune supplement to help maintain a healthy digestive function and liver. It also develops Travelan (IMM-124E), which is in Phase II clinical trial, to reduce the risk of contracting travelers' diarrhea; and IMM-529, which is in Phase II clinical trial, for treating patients suffering from recurring clostridium difficile infection. In additon, the company develops IMM-986, that is in pre-clinical stage. Further, it offers technology platform. The company has a collaboration with the US Naval Medical Research Command and Silver Spring, MD, USA to develop and clinically evaluate a therapeutic targeting Campylobacter and enterotoxigenic Escherichia coli infections; and a research collaboration with the Walter Reed Army Institute of Research to develop three Shigella-specific therapeutic products. The company was formerly known as Anadis Limited and changed its name to Immuron Limited in December 2008. Immuron Limited was incorporated in 1994 and is headquartered in Carlton, Australia. |
| Long Name | Immuron Limited |
| Market | us_market |
| Market Cap | 9,518,392 |
| Market State | REGULAR |
| Max Age | 86,400 |
| Message Board Id | finmb_7687411 |
| Most Recent Quarter | 1,767,139,200 |
| Net Income To Common | -4,646,242 |
| Next Fiscal Year End | 1,782,777,600 |
| Non Diluted Market Cap | 7,453,972 |
| Number Of Analyst Opinions | 1 |
| Open | 0.96 |
| Operating Cashflow | -4,696,813 |
| Operating Margins | -0.47155 |
| Payout Ratio | 0.0 |
| Phone | 61 3 9824 5254 |
| Previous Close | 0.9579 |
| Price Hint | 4 |
| Price To Book | 0.8164178 |
| Price To Sales Trailing12 Months | 1.2730198 |
| Profit Margins | -0.6214 |
| Quick Ratio | 6.747 |
| Quote Source Name | Nasdaq Real Time Price |
| Quote Type | EQUITY |
| Recommendation Key | none |
| Region | US |
| Regular Market Change | -0.02639997 |
| Regular Market Change Percent | -2.7560258 |
| Regular Market Day High | 0.96 |
| Regular Market Day Low | 0.9 |
| Regular Market Day Range | 0.9 - 0.96 |
| Regular Market Open | 0.96 |
| Regular Market Previous Close | 0.9579 |
| Regular Market Price | 0.9315 |
| Regular Market Time | 1,776,782,008 |
| Regular Market Volume | 3,194 |
| Return On Assets | -0.21931 |
| Return On Equity | -0.39683998 |
| Revenue Growth | 0.048 |
| Revenue Per Share | 1.16 |
| Sand P52 Week Change | 0.34445214 |
| Sector | Healthcare |
| Sector Disp | Healthcare |
| Sector Key | healthcare |
| Shares Outstanding | 8,166,340 |
| Shares Percent Shares Out | 0.0007 |
| Shares Short | 5,532 |
| Shares Short Previous Month Date | 1,772,150,400 |
| Shares Short Prior Month | 26,723 |
| Short Name | Immuron Limited |
| Short Percent Of Float | 0.0011 |
| Short Ratio | 0.24 |
| Source Interval | 15 |
| State | VIC |
| Symbol | IMRN |
| Target High Price | 4.004762 |
| Target Low Price | 4.004762 |
| Target Mean Price | 4.004762 |
| Target Median Price | 4.004762 |
| Total Cash | 9,995,328 |
| Total Cash Per Share | 0.031 |
| Total Debt | 203,914 |
| Total Revenue | 7,477,018 |
| Tradeable | 0 |
| Trailing Annual Dividend Rate | 0.0 |
| Trailing Annual Dividend Yield | 0.0 |
| Trailing Eps | -0.54 |
| Trailing Peg Ratio | None |
| Triggerable | 1 |
| Two Hundred Day Average | 1.39043 |
| Two Hundred Day Average Change | -0.45892996 |
| Two Hundred Day Average Change Percent | -0.33006334 |
| Type Disp | Equity |
| Volume | 3,194 |
| Website | https://www.immuron.com.au |
| Zip | 3,053 |